Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Intermittent Claudication: early-phase trial registry

3 of 12 indexed Intermittent Claudication trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 3 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Intermittent Claudication: 12 US clinical trials tracked, 3 recruiting.

Intermittent Claudication is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Northwestern University, running 2 of these trials.

Enrollment posture brief

Registry condition intermittent-claudication

OPEN 3 | RECR 25% | LATE 2 | EARLY 5 | RANK #1429 | SPON 2

Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)

Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Intermittent Claudicatio (th…25%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Intermittent Claudication

Intermittent Claudication lists 3 open slots (25% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Intermittent Claudication on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Intermittent Claudication is recruiting below its size-band peers.

    3 of 12 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Intermittent Claudication research.

    Northwestern University accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Typical Intermittent Claudication enrolment sits around 200 participants.

    Median target enrolment is 200 among the 12 trials that report a genuine target (sentinel values excluded). 4 of those (33.3%) plan for fewer than 100 participants.

  4. Intermittent Claudication research is mostly interventional.

    11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 24Phase 32

Open and recent trials

12 total, page 1 of 1

RECRUITING Phase 3 386 participants

Improving Mobility After Revascularization in Peripheral Artery Disease

Northwestern University

NCT06686121

RECRUITING Phase 2 200 participants

Response to Exercise and Nitric Oxide in PAD

Northwestern University

NCT06657976

RECRUITING Phase 3 200 participants

MetfOrmin BenefIts Lower Extremities With Intermittent Claudication

VA Office of Research and Development

NCT05132439

ACTIVE NOT RECRUITING NA 333 participants

The Chocolate Touch Study

TriReme Medical

NCT02924857

COMPLETED Phase 2 553 participants

Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease

Sanofi

NCT00443287

COMPLETED Phase 2 289 participants

Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication

Genzyme, a Sanofi Company

NCT00117650

COMPLETED Phase 2 190 participants

A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease

BioMarin Pharmaceutical

NCT00403494

COMPLETED 100 participants

Distributed Registry

Stanford University

NCT03898570

COMPLETED NA 50 participants

Exercise Training for Patients With Poor Leg Circulation

US Department of Veterans Affairs

NCT00118560

COMPLETED NA 32 participants

Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions

Roxane Laboratories

NCT00602173

COMPLETED NA 24 participants

Ischemic Preconditioning Claudication Study

Medical College of Wisconsin

NCT03511157

COMPLETED Phase 1 21 participants

Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

Genovate Biotechnology Co., Ltd.,

NCT03480321

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 2

Named interventions

Most-linked intervention names on Intermittent Claudication records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

placebo Drug
2 trials
Attention Control Behavioral
2 trials
Physical walking Behavioral
1 trials
Saline (Placebo Control) Other
1 trials
Ad2/HIF-1α/VP16 Biological
1 trials
Physical exercise Behavioral
1 trials
PMR 200 mg Drug
1 trials
PMR 150 mg Drug
1 trials

US sites by state

Facility locations filed on Intermittent Claudication trials. A trial with sites in several states counts in each.

California 5 trials
Georgia 4 trials
Texas 3 trials
Pennsylvania 3 trials
Illinois 3 trials
Florida 3 trials
Missouri 2 trials
Michigan 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Intermittent Claudication page

12 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Intermittent Claudication condition card totals 12 registered trials; most-linked intervention placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.